Cargando…

Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial

BACKGROUND: Coagulation activation and venous thromboembolism (VTE) are hallmarks of malignant disease and represent a major cause of morbidity and mortality in cancer. Coagulation inhibition with low-molecular-weight heparin (LMWH) may improve survival specifically in small-cell lung cancer (SCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ek, L, Gezelius, E, Bergman, B, Bendahl, P O, Anderson, H, Sundberg, J, Wallberg, M, Falkmer, U, Verma, S, Belting, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834130/ https://www.ncbi.nlm.nih.gov/pubmed/29106448 http://dx.doi.org/10.1093/annonc/mdx716

Ejemplares similares

Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin
por: Gezelius, E., et al.
Publicado: (2018)

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)
por: Gezelius, Emelie, et al.
Publicado: (2022)

Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN—A Randomized Trial with Low Molecular Weight Heparin
por: Bendahl, Pär-Ola, et al.
Publicado: (2023)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

Enoxaparin-sodium/heparin: Heparin-induced thrombocytopenia: case report
Publicado: (2021)

Enoxaparin sodium/heparin: Heparin-induced thrombocytopenia: 2 case reports
Publicado: (2021)

Enoxaparin-sodium/heparin: Heparin-induced thrombocytopenia and lack of efficacy: case report
Publicado: (2020)

Enoxaparin sodium: Heparin-induced thrombocytopenia: case report
Publicado: (2021)

Enoxaparin-sodium/heparin: Lack-of-efficacy: case report
Publicado: (2022)

Enoxaparin sodium: Heparin-induced thrombocytopenia: case report
Publicado: (2021)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Enoxaparin-sodium/heparin/warfarin: Heparin-induced thrombocytopenia and elevated INR: case report
Publicado: (2021)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Aspirin/enoxaparin sodium/heparin: Bleeding: 3 case reports
Publicado: (2021)

Enoxaparin sodium/heparin/tenecteplase: Haematoma: 6 case reports
Publicado: (2022)

Aspirin/enoxaparin-sodium/heparin: Lack of efficacy: case report
Publicado: (2021)

Enoxaparin-sodium/low-molecular-weight-heparins: Retro-peritoneal haemorrhage: case report
Publicado: (2021)

Enoxaparin sodium/heparin/warfarin: Various toxicities: 3 case reports
Publicado: (2021)

Enoxaparin-sodium/heparin: Rectus sheath haematoma: 2 case reports
Publicado: (2021)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Modernization of Enoxaparin Molecular Weight Determination Using Homogeneous Standards
por: Arnold, Katelyn M., et al.
Publicado: (2017)

Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
por: Nicholson, Tricia, et al.
Publicado: (2001)

Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives
por: Tandon, Ritesh, et al.
Publicado: (2020)

Enoxaparin sodium/heparin/unspecified corticosteroid: Various toxcities: 2 case reports
Publicado: (2021)

Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial
por: Iraji, Fariba, et al.
Publicado: (2013)

Comparative Pharmacokinetic Profile of 3 Batches of Ovine Low-Molecular-Weight Heparin and 1 Batch of Branded Enoxaparin
por: Jeske, Walter, et al.
Publicado: (2018)

Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice
por: Swieton, Justyna, et al.
Publicado: (2021)

In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin
por: Alroomi, Moudhi, et al.
Publicado: (2022)

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients
por: Pawlowski, Colin, et al.
Publicado: (2021)

Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients
por: Samuel, Sophie, et al.
Publicado: (2023)

Comparison of the Effects of Enoxaparin and Heparin on Inflammatory Biomarkers in Patients with ST-segment Elevated Myocardial Infarction: A prospective Open Label Pilot Clinical Trial
por: Nasiripour, Somayyeh, et al.
Publicado: (2014)

Pregnancy outcome in women with mechanical prosthetic heart valvesat their first trimester of pregnancy treated with unfractionated heparin (UFH) or enoxaparin: A randomized clinical trial
por: Movahedi, Minoo, et al.
Publicado: (2020)

Double-Blind Randomized Clinical Trial to Examine the Pharmacokinetic and Clinical Impacts of Fixed Dose versus Weight-based Enoxaparin Prophylaxis: A Methodologic Description of the FIxed or Variable Enoxaparin (FIVE) Trial
por: Pannucci, Christopher J., et al.
Publicado: (2019)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention
por: Li, Zhi-Zhong, et al.
Publicado: (2018)

Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy
por: Oliynyk, Oleksandr, et al.
Publicado: (2021)

The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial
por: Feldt, Maria, et al.
Publicado: (2020)

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_84o3ktfgcb9r9fkc9kru1p04o4